JP2013531993A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531993A5
JP2013531993A5 JP2013515568A JP2013515568A JP2013531993A5 JP 2013531993 A5 JP2013531993 A5 JP 2013531993A5 JP 2013515568 A JP2013515568 A JP 2013515568A JP 2013515568 A JP2013515568 A JP 2013515568A JP 2013531993 A5 JP2013531993 A5 JP 2013531993A5
Authority
JP
Japan
Prior art keywords
antibody
fragment
seq
influenza
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013515568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531993A (ja
JP6050747B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/040982 external-priority patent/WO2011160083A1/en
Publication of JP2013531993A publication Critical patent/JP2013531993A/ja
Publication of JP2013531993A5 publication Critical patent/JP2013531993A5/ja
Application granted granted Critical
Publication of JP6050747B2 publication Critical patent/JP6050747B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013515568A 2010-06-17 2011-06-17 インフルエンザ受動免疫化に有用な抗体 Active JP6050747B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US61/355,978 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US61/443,103 2011-02-15
US201161445455P 2011-02-22 2011-02-22
US61/445,455 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Publications (3)

Publication Number Publication Date
JP2013531993A JP2013531993A (ja) 2013-08-15
JP2013531993A5 true JP2013531993A5 (OSRAM) 2014-07-31
JP6050747B2 JP6050747B2 (ja) 2016-12-21

Family

ID=45348575

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013515568A Active JP6050747B2 (ja) 2010-06-17 2011-06-17 インフルエンザ受動免疫化に有用な抗体

Country Status (12)

Country Link
US (1) US10676520B2 (OSRAM)
EP (1) EP2582721B1 (OSRAM)
JP (1) JP6050747B2 (OSRAM)
KR (1) KR101849738B1 (OSRAM)
CN (2) CN106397584A (OSRAM)
AU (2) AU2011268072C1 (OSRAM)
BR (1) BR112012032185A2 (OSRAM)
CA (1) CA2839421C (OSRAM)
DK (1) DK2582721T3 (OSRAM)
ES (1) ES2687706T3 (OSRAM)
RU (1) RU2635999C2 (OSRAM)
WO (1) WO2011160083A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861515A1 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
BR112015010817A8 (pt) 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
JP6595448B2 (ja) 2013-03-14 2019-10-23 コントラフェクト コーポレイション 治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
RU2720282C1 (ru) 2014-02-04 2020-04-28 Контрафект Корпорейшн Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
JP6718379B2 (ja) * 2014-03-20 2020-07-08 インフラルクス ゲーエムベーハー ウイルス性肺炎治療のためのC5aの阻害剤
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
WO2018011353A1 (en) * 2016-07-14 2018-01-18 Bioarctic Ab Brain delivery protein
WO2019133004A1 (en) * 2017-12-29 2019-07-04 Development Center For Biotechnology A universal vaccine against influenza
US11780907B2 (en) 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
CA3132521A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
KR20050114225A (ko) 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
WO2005007697A1 (ja) * 2003-07-23 2005-01-27 Fujirebio Inc. 抗インフルエンザa型ウイルスモノクローナル抗体及び該抗体を用いる免疫測定器具
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
US20080014205A1 (en) 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
EA017203B1 (ru) * 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP3524619A1 (en) * 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
EP2698380A1 (en) * 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
RU2553325C2 (ru) * 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
AR073072A1 (es) * 2008-08-19 2010-10-13 Regeneron Pharma Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano
CN102292350A (zh) * 2008-12-24 2011-12-21 淡马锡生命科学研究院有限公司 对来自甲型流感病毒血凝素的融合肽特异的单克隆抗体及其用途
EA029198B1 (ru) 2010-03-26 2018-02-28 Помона Ричерка С.Р.Л. Полноразмерные иммуноглобулины изотипа igg, способные к распознаванию нейтрализующего эпитопа в области стебля гемагглютинина различных подтипов и их использование в качестве лекарственного средства против гриппа
EP2603237A4 (en) * 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Similar Documents

Publication Publication Date Title
JP2013531993A5 (OSRAM)
CN104892753B (zh) 一种中和人感染h7n9甲型流感病毒的抗体及其用途
Lee et al. Structural characterization of viral epitopes recognized by broadly cross-reactive antibodies
RU2013102073A (ru) Антитела, подходящие для пассивной иммунизации против гриппа
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
AU2021245146A1 (en) Influenza A virus specific antibodies
JP6371222B2 (ja) インフルエンザの受動免疫用抗体
JP2011528901A5 (OSRAM)
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
JP2010521147A5 (OSRAM)
JP2014237714A5 (OSRAM)
JP2016503413A5 (OSRAM)
JP2010502207A5 (OSRAM)
JP2011528902A5 (OSRAM)
JP2015522252A5 (OSRAM)
JP2012526839A5 (OSRAM)
JP2013501807A5 (OSRAM)
US10610587B2 (en) Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same
CN105985433B (zh) 针对h7n9亚型禽流感病毒的全人源单克隆抗体及应用
CN111094335A (zh) 广泛中和的抗流感单克隆抗体及其用途
CN101993492B (zh) 抗H5N1型高致病性禽流感scFv抗体及其应用
CN107216387B (zh) 一种b型流感病毒广谱中和抗体、其制备方法及应用
Wu et al. Allosteric Neutralization by Human H7N9 Antibodies
Jia et al. Allosteric Neutralization by Human H7N9 Antibodies
Voronina et al. Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection